This discovery may lead to a novel treatment approach that targets underlying brain pressure mechanisms rather than just managing symptoms. The research suggests that liraglutide, a drug originally ...

Around five million Australians suffer from migraines, with women three times more likely to be affected than men ...

Over 12 weeks, 26 patients suffering frequent migraines and obesity received a daily dose of the GLP-1 agonist liraglutide. Remarkably, the average number of migraine days per month fell sharply ...

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life improvements occurring despite minimal weight changes.

Ozempic is approved in Canada as a treatment for type 2 diabetes, though it has garnered headlines for its off-label use as a weight-loss drug.

Blockbuster weight-loss shots like Ozempic, Wegovy and Victoza may have an unexpected side effect impacting as many as 47million Americans, a new study from researchers in Italy found.

After years of persistent shortages, Canadians can now access Wegovy, an on-label weight loss medication, made by the same manufacturers of Ozempic.. Novo Nordisk’s drug officially hit the ...